Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2015.03.004
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2015
Authors
Publisher
Elsevier BV